|
In September 2006, Sonus initiated a Phase 1 study of SN2310, a novel
camptothecin for the treatment of cancer.
What are
Camptothecins?
4
Potent
anticancer agents that belong to the family of drugs called
topoisomerase I inhibitors.
4
Bind reversibly to the TOPO-I-DNA complex causing breaks in the DNA strands during
replication– resulting in cell death
4
Due to
cell-cycle dependence and reversible binding - prolonged exposure of
tumors to camptothecins is necessary for effective biological
activity1
(1.
Clin
Cancer Res. 2005; 11(11):4144-4150.)
Approved
Topoisomerase I Inhibitors
|
|
Irinotecan (Camptosar®) |
Topotecan (Hycamtin®) |
|
Indications |
Metastatic
colorectal cancer Component
of 1st line with 5-FU and
leucovorin
or
when disease has recurred or
progressed
following initial
5-FU- based therapy |
Ovarian (2nd
line)
SCLC (2nd
line) |
|
2006 Sales
($MM) |
$ 903 (WW) |
$ 225 (WW) |
|
Limitations |
Pro-drug
requires enzymatic hydrolysis with approx. 3% conversion
to active drug (SN38)
Half-life: Irinotecan = 5.8 hours
SN-38 = 10.4 hours
Diarrhea
is a DLT |
Short
half-life requires daily dosing |
Structural
Comparison of SN2310 and Irinotecan
SN2310: The Value
Proposition
|
Enhanced
PK |
4
Longer
half life and higher exposure to SN-38
4
Potential
for improved anti-tumor activity and/or better tolerability
4
Potentially more convenient dosing schedules in combination
therapy
|
|
Convenience/Ease of Use |
4
Reduced
duration of administration
4
Ready-to-use formulation
|
|
Intellectual Property |
4
1 issued
US COM patent; other geographies pending
|
|